Atlas Trials

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT04659044 · TERMINATED

Trial details

NCT number
NCT04659044
Sponsor
Academic and Community Cancer Research United
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular LymphomaRefractory Mantle Cell Lymphoma
Start date
2021-04-01
Primary completion
2024-03-28
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.